Inverse Agonist Activity of Selected Ligands of the Cysteinyl-Leukotriene Receptor 1

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 1, 2004, Pages 102-108

  Dupré, Denis J ^a   Le Gouill, Christian ^a   Gingras, Denis ^a   Rola Pleszczynski, Marek ^a   Staňková, Jana ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; CYSTEINYL LEUKOTRINE RECEPTOR 1; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL PHOSPHATE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CELL STRAIN COS7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL;

ACETATES; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GTP-BINDING PROTEINS; HUMANS; LEUKOTRIENE ANTAGONISTS; MEMBRANE PROTEINS; PROPIONATES; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, LEUKOTRIENE; TOSYL COMPOUNDS; TRANSFECTION;

EID: 1642371108     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.059824     Document Type: Article

References (44)

1. Adan RA and Kas MJ (2003) Inverse agonism gains weight. Trends Pharmacol Sci 24:315-321.
2. Adolfsson JL, Ohd JF, and Sjolander A (1996) Leukotriene D4-induced activation and translocation of the G-protein alpha i3-subunit in human epithelial cells. Biochem Biophys Res Commun 226:413-419.
3. Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y, and Kawakami Y (1998) Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Crit Care Med 157:1907-1912.
4. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, and Leurs R (2001) Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 60:1133-1142.
5. Barker EL, Westphal RS, Schmidt D, and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
6. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, et al. (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature (Lond) 374:272-276.
7. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
8. Burstein ES, Spalding TA, and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
9. Callaerts-Vegh Z, Evans KL, Shipley GL, Davies PJ, Cuba DL, Gurji HA, Giles H, and Bond RA (2003) Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery. Br J Pharmacol 138:1505-1516.
10. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45:490-499.
11. Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, and Grunstein MM (1995) Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol 269:L151-L157.
12. Costa T, Ogino Y, Munson PJ, Onaran HO, and Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560.
13. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, Seidenberg BC, Zwinderman AH, Peszek I, and Sterk PJ (1999) The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 29:42-51.
14. Dupre DJ, Le Gouill C, Rola-Pleszczynski M, and Stankova J (2001) Inverse agonist activity of selected ligands of platelet-activating factor receptor. J Pharmacol Exp Ther 299:358-365.
15. Espinosa K, Bosse Y, Stankova J, and Rola-Pleszczynski M (2003) CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 111:1032-1040.
16. Evans JF (2002) Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat 68-69:587-597.
17. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
18. Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, Jonas M, Pae C, Wang H, and Chi EY (2002) A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165:108-116.
19. Hui Y and Funk CD (2002) Cysteinyl leukotriene receptors. Biochem Pharmacol 64:1549-1557.
20. Jarvis B and Markham A (2000) Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 59:891-928.
21. Lee TW, Cotecchia S, and Milligan G (1997) Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists. Biochem J 325:733-739.
22. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
23. Lefkowitz RJ, Cotecchia S, Samama P, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
24. Leurs R, Smit MJ, Alewijnse AE, and Timmerman H (1998) Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem Sci 23:418-422.
25. Li J, Chen C, Huang P, and Liu-Chen LY (2001) Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60:1064-1075.
26. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature (Lond) 399:789-793.
27. Milligan G, Bond RA, and Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16:10-13.
28. Newman-Tancredi A, Conte C, Chaput C, Spedding M, and Millan MJ (1997) Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-739.
29. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, and Hay DW (1998) Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19:453-461.
30. Parent JL, Le Gouill C, de Brum-Fernandes AJ, Rola-Pleszczynski M, and Stankova J (1996a) Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor. J Biol Chem 271:7949-7955.
31. Parent JL, Le Gouill C, Rola-Pleszczynski M, and Stankova J (1996b) Mutation of an aspartate at position 63 in the human platelet-activating factor receptor augments binding affinity but abolishes G-protein-coupling and inositol phosphate production. Biochem Biophys Res Commun 219:968-975.
32. Pauwels PJ and Tardif S (2002) Enhanced stability of wild-type and constitutively active alpha(2A)-adrenoceptors by ligands with agonist, silent and inverse agonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 366:134-141.
33. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO (Eur Mol Biol Organ) J 21:1628-1637.
34. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, and Miller LJ (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51:357-362.
35. Samama P, Pei G, Costa T, Cotecchia S, and Lefkowitz RJ (1994) Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol 45:390-394.
36. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, Schmidt DB, Muccitelli RM, Jenkins O, Murdock PR, et al. (1999) Identification, molecular cloning, expression and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56:657-663.
37. Schwartz JC, Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, and Arrang JM (2003) Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. J Neural Transm Suppl 64:1-16.
38. Seifert R and Wenzel-Seifert K (2003) The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors. Life Sci 73:2263-2280.
39. Shryock JC, Ozeck MJ, and Belardinelli L (1998) Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol 53:886-893.
40. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y, Roovers E, and Timmerman H (1996) Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci USA 93:6802-6807.
41. Smith LJ, Glass M, and Minkwitz MC (1993) Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 54:430-436.
42. Spadoni G, Balsamini C, Bedini A, Diamantini G, Di Giacomo B, Tontini A, Tarzia G, Mor M, Plazzi PV, Rivara S, et al. (1998) 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists and putative inverse agonists. J Med Chem 41:3624-3634.
43. Wilson MH and Limbird LE (2000) Mechanisms regulating the cell surface residence time of the alpha 2A-adrenergic receptor. Biochemistry 39:693-700.
44. Zhu J, Taniguchi T, Takauji R, Suzuki F, Tanaka T, and Muramatsu I (2000) Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor. Br J Pharmacol 131:546-552.